Premium
Safety, tolerability and satisfaction with tegaserod therapy in Asia–Pacific patients with irritable bowel syndrome with constipation
Author(s) -
Fock Kwong M,
Wagner Amy
Publication year - 2007
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.2007.04955.x
Subject(s) - tegaserod , tolerability , medicine , constipation , irritable bowel syndrome , adverse effect , abdominal pain , diarrhea , placebo , alternative medicine , pathology
Background and Aim: The 5‐HT 4 receptor agonist tegaserod (6 mg b.i.d.) provides significantly better overall multiple symptom relief compared with placebo in patients with irritable bowel syndrome with constipation (IBS‐C). The clinical benefit and safety of tegaserod in IBS‐C patients has been demonstrated worldwide in several studies. The aim of this study was to obtain further safety and tolerability data in patients with IBS in the Asia–Pacific region, and to assess patients' satisfaction and compliance with treatment and willingness to re‐use tegaserod in a post‐marketing setting. Methods: A multicenter, single‐arm, open‐label trial was conducted at 869 outpatient centers in 10 countries. Men and women with IBS, whose predominant bowel symptom was not diarrhea (non‐D‐IBS), received tegaserod for 4–12 weeks. Safety and tolerability were assessed by recording adverse events (AE). Patients were questioned about compliance, satisfaction with treatment and willingness to use tegaserod in future. Results: Data were available from 14 537 patients (18% men, 82% women). Four percent of patients reported at least one AE. The most common AE were diarrhea (2%) and abdominal pain (1%), and most treatment‐related AE occurred in the first week of treatment. Serious AE (SAE) were observed in eight patients, and no deaths were reported. Most patients (79%) reported to be satisfied or very satisfied with treatment, and 76% stated they would use tegaserod in the future. Compliance was 97%. Conclusions: Tegaserod has a favorable safety and tolerability profile for treating non‐D‐IBS and IBS‐C in men and women in the Asia–Pacific region. Satisfaction with tegaserod treatment can be expected in the majority of patients.